RICHLAND, Wash.--(BUSINESS WIRE)--June 9, 2006--IsoRay, Inc. (“IsoRay”) (OTCBB:ISRY - News), a medical technology company focusing on innovative treatment for prostate cancer and other solid cancer tumors through use of its proprietary Cesium-131 brachytherapy seeds, announced that the Securities and Exchange Commission has declared its Registration Statement effective yesterday at 5 p.m. (Eastern Time).
